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A B S T R A C T
Background
Pancreatic pseudocysts arewalled-off peripancreatic fluid collections. There is considerable uncertainty about howpancreatic pseudocysts
should be treated.
Objectives
To assess the benefits and harms of different management strategies for pancreatic pseudocysts.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library 2015, Issue 9, and MEDLINE,
EMBASE, Science Citation Index Expanded, and trials registers until September 2015. We also searched the references of included
trials and contacted trial authors.
Selection criteria
We only considered randomised controlled trials (RCTs) of people with pancreatic pseudocysts, regardless of size, presence of symptoms,
or aetiology. We placed no restrictions on blinding, language, or publication status of the trials.
Data collection and analysis
Two review authors independently identified trials and extracted data. We calculated the odds ratio (OR) and mean difference (MD)
with 95% confidence intervals (CI) with RevMan 5, based on an available-case analysis for direct comparisons, using fixed-effect and
random-effect models. We also conducted indirect comparisons (rather than network meta-analysis), since there were no outcomes for
which direct and indirect evidence were available.
Main results
We included four RCTs, with 177 participants, in this review. After one participant was excluded, 176 participants were randomised
to endoscopic ultrasound (EUS)-guided drainage (88 participants), endoscopic drainage (44 participants), EUS-guided drainage with
nasocystic drainage (24participants), and open surgical drainage (20 participants). The comparisons included endoscopic drainage versus
EUS-guided drainage (two trials), EUS-guided drainage with nasocystic drainage versus EUS-guided drainage alone (one trial), and
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open surgical drainage versus EUS-guided drainage (one trial). The participants were mostly symptomatic, with pancreatic pseudocysts
resulting from acute and chronic pancreatitis of varied aetiology. The mean size of the pseudocysts ranged between 70 mm and 155
mm across studies. Although the trials appeared to include similar types of participants for all comparisons, we were unable to assess
this statistically, since there were no direct and indirect results for any of the comparisons.
All the trials were at unclear or high risk of bias, and the overall quality of evidence was low or very low for all outcomes. One death
occurred in the endoscopic drainage group (1/44; 2.3%), due to bleeding. There were no deaths in the other groups. The differences
in the serious adverse events were imprecise. Short-term health-related quality of life (HRQoL; four weeks to three months) was worse
(MD -21.00; 95% CI -33.21 to -8.79; participants = 40; studies = 1; range: 0 to 100; higher score indicates better) and the costs
were higher in the open surgical drainage group than the EUS-guided drainage group (MD 8040 USD; 95% CI 3020 to 13,060;
participants = 40; studies = 1). There were fewer adverse events in the EUS-guided drainage with nasocystic drainage group than in the
EUS-guided drainage alone (OR 0.20; 95% CI 0.06 to 0.73; participants = 47; studies = 1), or the endoscopic drainage group (indirect
comparison: OR 0.08; 95% CI 0.01 to 0.61). Participants with EUS-guided drainage with nasocystic drainage also had shorter hospital
stays compared to EUS-guided drainage alone (MD -8.10 days; 95% CI -9.79 to -6.41; participants = 47; studies = 1), endoscopic
drainage (indirect comparison: MD -7.10 days; 95% CI -9.38 to -4.82), or open surgical drainage group (indirect comparison: MD
-12.30 days; 95% CI -14.48 to -10.12). The open surgical drainage group had longer hospital stays than the EUS-guided drainage
group (MD 4.20 days; 95% CI 2.82 to 5.58; participants = 40; studies = 1); the endoscopic drainage group had longer hospital stays
than the open drainage group (indirect comparison: -5.20 days; 95% CI -7.26 to -3.14). The need for additional invasive interventions
was higher for the endoscopic drainage group than the EUS-guided drainage group (OR 11.13; 95% CI 2.85 to 43.44; participants
= 89; studies = 2), and the open drainage group (indirect comparison: OR 23.69; 95% CI 1.40 to 400.71). The differences between
groups were imprecise for the other comparisons that could be performed. None of the trials reported long-term mortality, medium-
term HRQoL (three months to one year), long-term HRQoL (longer than one year), time-to-return to normal activities, or time-to-
return to work.
Authors’ conclusions
Very low-quality evidence suggested that the differences in mortality and serious adverse events between treatments were imprecise.
Low-quality evidence suggested that short-termHRQoL (four weeks to three months) was worse, and the costs were higher in the open
surgical drainage group than in the EUS-guided drainage group. Low-quality or very low-quality evidence suggested that EUS-guided
drainage with nasocystic drainage led to fewer adverse events than EUS-guided or endoscopic drainage, and shorter hospital stays when
compared to EUS-guided drainage, endoscopic drainage, or open surgical drainage, while EUS-guided drainage led to shorter hospital
stays than open surgical drainage. Low-quality evidence suggested that there was a higher need for additional invasive procedures with
endoscopic drainage than EUS-guided drainage, while it was lower in the open surgical drainage than in the endoscopic drainage group.
FurtherRCTs are needed to compare EUS-guideddrainage, with orwithout nasocystic drainage, in symptomatic patientswith pancreatic
pseudocysts that require treatment. Future trials should include patient-oriented outcomes such as mortality, serious adverse events,
HRQoL, hospital stay, return-to-normal activity, number of work days lost, and the need for additional procedures, for a minimum
follow-up period of two to three years.
P L A I N L A N G U A G E S U M M A R Y
Treatment methods for people with pancreatic pseudocysts (fluid collections around the pancreas)
Review question
How should people with pancreatic pseudocysts be treated?
Background
The pancreas is an abdominal organ that secretes several digestive enzymes (substances that enable and speed up chemical reactions in
the body) into the pancreatic ductal system, which empties into the small bowel. It also contains the Islets of Langerhans, which secrete
several hormones, including insulin (that helps to regulate blood sugar). Pancreatic pseudocysts are fluid collections around the pancreas.
They arise due to sudden or long-standing inflammation of the pancreas. While some will disappear when the inflammation of the
pancreas settles down, others remain and cause symptoms such as abdominal pain, indigestion, vomiting, and weight loss. Treatments
of pancreatic pseudocysts include conservative treatment (watchful monitoring), surgical drainage, which can be performed through
a standard cut (open surgical drainage) or by key-hole surgery (laparoscopic surgical drainage), or endoscopic drainage. In endoscopic
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drainage, a tube (stent) is inserted with the help of an endoscope (a tube passed through the mouth into the stomach, usually to visualise
the abdominal organs from inside the body), that connects the pseudocyst to the stomach or the upper part of the small intestine.
The insertion may be further helped by using an endoscopic ultrasound (an ultrasound probe attached to the endoscope; EUS-guided
drainage). Endoscopic ultrasound-guided drainage may be further assisted by passing a tube through the nose and inserting it into the
cyst during EUS-guided drainage (EUS-guided drainage with nasocystic drainage). The best way to treat pancreatic pseudocysts is not
clear. We sought to resolve this by searching for existing studies on the topic. We included all randomised controlled trials whose results
were reported up to 8 September 2015. Apart from using standard Cochrane methods, which allow comparison of only two treatments
at a time (direct comparison), we used advanced methods, which allow individual comparison of the different treatments compared in
the trials (indirect comparison).
Study characteristics
We included four trials, with 177 participants, in the review, 176 of whom were included in the analyses. The treatments compared
in the four trials included endoscopic drainage (without EUS guidance), EUS-guided drainage, EUS-guided drainage with nasocystic
drainage, and open surgical drainage. The participants were mostly people with pancreatic pseudocysts resulting from sudden onset or
long-term inflammation of the pancreas, from different causes.
Key results
One death occurred in the endoscopic drainage group, due to bleeding. The differences in the serious complications were imprecise.
Short-term health-related quality of life (HRQoL; four weeks to three months) was worse, and the costs were higher in the open surgical
drainage group than in the EUS-guided drainage group. There were fewer complications of any severity (such as bleeding) that required
additional treatment in the EUS-guided drainage with nasocystic drainage group than in the EUS-guided drainage alone or endoscopic
drainage groups. Those who received EUS-guided drainage with nasocystic drainage also had a shorter hospital stay compared to those
who received EUS-guided drainage alone, endoscopic drainage, or open surgical drainage. Those who received EUS-guided drainage
alone had shorter hospital stays than those with open surgical drainage. There was a higher need for additional invasive treatments to
completely drain the pseudocyst with endoscopic drainage than EUS-guided drainage alone. The differences for the other comparisons
were imprecise. None of the trials reported long-term deaths, medium-term or long-term HRQoL, time-to-return to normal activities,
or time-to-return to work.
Quality of the evidence
The overall quality of evidence was low or very low for all the outcomes, because the trials were small and at high risk of bias (for
example, prejudice of people who conduct the trial, and trial participants who prefer one treatment over another). As a result, further
studies are required on this topic. Such studies should compare EUS-guided drainage with or without nasocystic drainage in people who
have symptoms from their pancreatic pseudocysts and need treatment. Such trials should should measure patient-oriented outcomes
for a minimum follow-up period of two to three years.
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